MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

SpringWorks Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

43.26 -6.99

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

43.01

Max

46.51

Schlüsselkennzahlen

By Trading Economics

Einkommen

-24M

-77M

Verkäufe

12M

62M

EPS

-1.04

Gewinnspanne

-125.586

Angestellte

368

EBITDA

-23M

-80M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.15% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

1. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-839M

3.3B

Vorheriger Eröffnungskurs

50.25

Vorheriger Schlusskurs

43.26

Nachrichtenstimmung

By Acuity

50%

50%

166 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

SpringWorks Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Feb. 2025, 07:03 UTC

Akquisitionen, Fusionen, Übernahmen

Germany's Merck in Talks to Buy SpringWorks Therapeutics

10. Feb. 2025, 16:38 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

SpringWorks Therapeutics Shares Rise on Report it May be Acquired

11. Feb. 2025, 10:54 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk

11. Feb. 2025, 10:52 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Peer-Vergleich

Kursveränderung

SpringWorks Therapeutics Inc Prognose

Kursziel

By TipRanks

54.15% Vorteil

12-Monats-Prognose

Durchschnitt 71.71 USD  54.15%

Hoch 87 USD

Tief 63 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für SpringWorks Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

7

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

41.3 / 46.48Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

166 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.